Principles of effective out-patient diagnostics of diffuse liver diseases
Abstract
Aim of investigation. To study prevalence of diffuse liver diseases in the Russian Federation by the example of large industrial city with application of screening tests.
Material and methods. Overall 5000 Moscow inhabitants age 18 to 75 years, chosen randomly within the «the liver check up» project, have been included in prospective population study. All patients underwent following investigation: physical examination, filling of nutrition diary, CAGE and AUDIT questionnaires, taking occupational history, anthopometrical examination, US of abdominal organs, clinical and biochemical blood tests, assessment of HCVAb and HBsAg. In the case of abnormal liver tests preliminary diagnosis was determined according to certain algorithm and these patients were recruited for further investigation and specifications of diagnosis in department of hepatology, University clinical hospital N 2, State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university».
Results. Abnormal liver functional tests were revealed in 30,6% of industrial city inhabitants — in 1461 of 4768 cases (232 patients were excluded from the study due to partial data loss), significantly more frequently in men in comparison to women, i.e. 49,7 and 25,5% respectively (p<0,001). Prevalence of diffuse liver diseases in the studied sample (n=4768) was following: non-alcoholic fatty liver disease —7,4% (n=352), alcohol-induced liver disease — 6,9% (n=329), hepatitis C — 6,7% (n=322), hepatitis B — 1,9% (n=91), drug-induced liver disease — 0,82% (n=39), cholestatic liver diseases — 0,69 % (n=33), autoimmune hepatitis — 0,78% (n=37), others — 5,4% (n=258).
Conclusion. Risk factors for diseases, defined by one-way ANOVA test, were: male gender (p<0,001), excessive body weight and obesity (body mass index >25 kg/m2 (p<0,001)), hyperglycemia (p<0,001), hypertriglyceridemia (p<0,001). By more strict estimation at multifactorial analysis major risk factors were determined: age 30 to 59 years (p<0,001), intake of alcoholic beverages in harmful dozes (over 16 points of AUDIT questionnaire, p=0,04), hypercholesterolemia (p=0,016). Relative weight of those, requiring etiological and pathogenic treatment after specification of preliminary diagnosis, of patients with abnormal liver tests, revealed at screening stage, was 80,3%.
About the Authors
Komova A. G.
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of Russian Federation
Russian Federation
Russian Federation
Komova Anna G — physician of therapeutic and diagnostic department N 3, Vasilenko Clinic of internal diseases propedeutics, gastroenterology and hepatology, post-graduate student of Chair of internal diseases propedeutics,
medical faculty
119991, Moscow, Pogodinskaya street, 1, bld 1
M. V. Mayevskaya
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of Russian Federation
Russian Federation
Russian Federation
Mayevskaya Marina V — MD, PhD, professor, Vasilenko Clinic of internal diseases propedeutics, gastroenterology and hepatology
119991, Moscow, Trubetskaya street, 8, bld 2.
V. T. Ivashkin
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of Russian Federation
Russian Federation
Russian Federation
References
1. Буеверов А.О., Готье С.В., Ерамишанцев А.К., Жданов К.В., Ивашкин В.Т., Лобзин Ю.В., Маевская М.В., Никитин И.Г., Чжао А.В. Диагностика и лечение диффузных заболеваний печени: Методическое пособие / Под ред. В.Т. Ивашкина, Н.Д. Ющука. М., 2003.
2. Драпкина О.М., Гацолаева Д.С., Ивашкин В.Т. Неалкогольная жировая болезнь печени как компонент метаболического синдрома. Рос мед вести 2010; 15(2):72-8.
3. Ивашкин В.Т., Маевская М.В. Алкогольно-вирусные заболевания печени. М., 2007; 156 с.
4. Ивашкин В.Т., Павлов Ч.С. Фиброз печени. М.: ГЭОТАР Медиа, 2011.
5. Маевская М.В., Ивашкин В.Т., Герман Е.Н. Правила обследования пациентов с бессимптомным повышением активности сывороточных аминотрансфераз. Рос журн гастроэнтерол гепатол колопроктол 2013; 23(4):45-68.
6. Маевская М.В. Хронические диффузные заболевания печени, вызванные алкоголем и вирусами гепатитов В и С: Дис. ... д-ра мед. наук. М., 2006.
7. Шахгильдян И.В., Ершова О.Н., Михайлов М.И. и др. Современная характеристика острого и хронического гепатита С в России: Материалы междунар. симпозиума. – Брест, 2011:184-6.
8. Широкова Е.Н. Холестаз при хронических диффузных заболеваниях печени: патогенез, дифференциальный диагноз, прогностическое значение, лечебная тактика. Дис. ... д-ра мед. наук. М., 2009.
9. Bedogni G., Miglioli L., Masutti F., Castiglione A., Croce L.S., Tiribelli C., et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007; 46:1387-91.
10. Bell B.P., Manos M.M., Zaman A. The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am J Gastroenterol 2008; 103(11):2727-36.
11. Chalasani Naga, Younossi Zobair et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association, 2012.
12. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update, 2009. AASLD Practice Guideline update.
13. Imhof A., Kratzer W., Boehm B., Meitinger K., Trischler G., Steinbach G., et al. Prevalence of nonalcoholic fatty liver and characteristics in overweight adolescents in the general population. Eur J Epidemiol 2007; 22:889-97.
14. Kim W.R., Brown R.S.Jr, Terrault N.A., et al. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36:227-42.
15. Lindor Keith D., Gershwin M. Eric, Poupon Raoul, et al. Primary biliary cirrhosis. AASLD Practice guidelines, 2009.
16. Lok Anna S.F., McMahon B.J. Chronic hepatitis B: update 2009. AASLD Practice guideline update.
17. Manns Michael P., Czaja Albert J., Gorham James D., et al. Diagnosis and management of autoimmune hepatitis, AASLD Practice guidelines, 2010.
18. Martin Blachier, Henri Leleu, Markus PeckRadosavljevic, Dominique-Charles Valla, Françoise Roudot-Thoraval The Burden of liver disease in Europe. A review of available epidemiological data, 2013.
19. Muhlberger N., Schwarzer R., Lettmeier B., Sroczynski G., Zeuzem S., Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009; 9:34.
20. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 2003; 37:1202-19.
21. O’Shea Robert S., Dasarathy Srinivasan, Arthur J. McCullough, and the Practice Guideline Committee of the American Association for the Study of Liver Diseases and the Practice Parameters Committee of the American College of Gastroenterology. Alcoholic Liver Disease, Hepatology 2010.
22. Radu C., Grigorescu M., Crisan D., Lupsor M., Constantin D., Dina L. Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. J Gastrointestin Liver Dis 2008; 17:255-60.
23. Rautiainen H., Salomaa V., Niemela S., Karvonen A.L., Nurmi H., Isoniemi H., et al. Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. Scand J Gastroenterol 2007; 42:1347-53.
Review
For citations:
G. K.A., Mayevskaya M.V., Ivashkin V.T. Principles of effective out-patient diagnostics of diffuse liver diseases. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(5):36-41. (In Russ.)
Views:
95
Email this article 
